@nephroseeker.medsky.social
🩺 Nephrologist = kidney philosopher 📜History lover 🕊️ Aspiring to be better. Freethinker 📍 #NephJC editor-in-chief 📍@KIreportsbsky.social 📍ERAkidney #ERA26 social media co-leader #NephSky #MedSky
@nephjc.bsky.socialReposted by @nephroseeker.medsky.social12 years of #NephJC. Countless papers discussed, ideas challenged, and friendships made.
🩵No paywalls. No pharma funding, just a community that believes in free, independent nephrology education.
🌟We need your help to keep it going. Please donate
@nephjc.bsky.socialReposted by @nephroseeker.medsky.social11/10 ➡️Up next on 10/13: Survival benefit of deceased donor kidney transplantation versus continued dialysis: international target trial emulation | The BMJ
www.bmj.com/content/394/...
Join us www.nephjc.com/
@nephjc.bsky.socialReposted by @nephroseeker.medsky.social@nephjc.bsky.socialReposted by @nephroseeker.medsky.socialCan tolvaptan keep up with 3% saline?
This within-subject study in healthy volunteers delivered a surprising answer - and a few eyebrow-raising physiology twist. Dive in #NephJC
✍️ by @drsaivani.bsky.social
@nephroseeker.medsky.social8/ Future trials must fix the usual pitfalls:
🚩 Phenotype enrichment (LVH, high K gradient, volume overload)
🚩 Blinded adjudication
🚩Explicit competing-risk modeling
🚩Patient burden metrics
#Nephsky
@nephroseeker.medsky.social7/ Longer/ frequent dialysis reduces UF stress and smooths electrolytes. But hard CV outcomes remain scarce. Trials are often underpowered, single-center, and ignore competing risks like transplant or withdrawal.
@nephroseeker.medsky.social6/ Incremental dialysis may “preserve RRF,” but current evidence is observational, biased, and non‑adjudicated. Healthier patients are selected, not randomized. CV benefit is unproven. Only high‑RRF incident patients with strict monitoring fit the strategy
@nephroseeker.medsky.social5/ Dialysate sodium can be seen as a CV prescription, but current evidence is shaky. Trials are small, underpowered, with non-adjudicated endpoints and inconsistent CMR-LV mass results. ⬇️sodium reduces IDWG/BP yet ⬆️ hypotension. Most studies ignore competing risks+ antihypertensive confounding
@nephroseeker.medsky.social4/ Potassium gradients drive arrhythmia. Continuous monitoring shows AV/VAs cluster around dialysis. But current studies are small, crossover, and underpowered
@nephroseeker.medsky.social3/ HDx clears larger middle molecules, yet no cardiovascular outcome benefit. Neutral PWV, neutral echo, and rising CAC in HDx. Biology doesn't guarantee outcomes. 🎯Phenotype-enriched, adjudicated trials needed
@nephroseeker.medsky.social2/ High-volume HDF shows the strongest survival signal - but we must stay critical. Prior trials had center effects, adherence bias, and achieved-dose confounding. CONVINCE helps, but the mechanism remains opaque
@nephroseeker.medsky.socialDialysis adequacy MUST move beyond urea kinetics, and some of us have stated this for years.
🫀The dominant threat is cardiovascular stress: volumes, electrolytes, arrhythmia, LV load, inflammation... Kt/V is not enough #Nephsky
@kireports.bsky.socialReposted by @nephroseeker.medsky.social1/ HELLP syndrome is usually lumped with #preeclampsia as “the same disease”. This nationwide French study (CONCEPTION) shows that isolated PE (iPE) & PE-HELLP actually diverge in risk factors AND outcomes
Why does it matter?
@nephroseeker.medsky.socialPreeclampsia and PE-HELLP are often grouped as the same disease, but are they?
New nationwide French data from CONCEPTION show distinct risk factors and outcomes, raising a key question: do they carry the same long-term cardiovascular and kidney risk?
@kireports.bsky.socialReposted by @nephroseeker.medsky.social1/ 🚨Tweetorial Alert🚨
Hey #NephSky! Welcome to a 🆕 #skeetorial brought to you by @KIReports @ISNkidneycare. Please also check out www.kireportscommunity.org educational #blogposts. FOLLOW US!
@hswapnil.medsky.socialReposted by @nephroseeker.medsky.socialIt’s official - EASiKidney - one of the largest kidney trials at ~ 15000 is terminated early
www.boehringer-ingelheim.com/human-health...
A setback for ASI in CKD (they are going strong in hypertension of course)
@nephjc.bsky.socialReposted by @nephroseeker.medsky.social⏳ Just a bit over one month until #KidneyWk
And yes... the legendary #NephJC party is happening again 🎉
🩵Join us, meet the crew, and meet people from across the world
👇Grab your ticket and come be part of the magic
www.nephjc.com/news/2026/9/...
@hswapnil.medsky.socialReposted by @nephroseeker.medsky.socialYou want a ticket to the hottest event of #KidneyWk?
www.nephjc.com/news/2026/9/...
Consider a donation to the fall #NephJC pledge drive
@nephroseeker.medsky.social#NephJC helped me find my voice and my people- a global community I'm proud to be part of. We can only continue this work with your support 🩵
Donate to keep the magic going 🪄✨
@nephroseeker.medsky.social